FGF2 and chronic kidney disease: ADSCs secretome is the principal mechanism suggested for mediating the antifibrogenic effect; VEGF, HGF, FGF-2, among other growth factors, could promote angiogenesis and renal regeneration processes [40,41]; and matrix metalloproteinases (MMPs) [8] that are traditionally conceived as antifibrotic agents in the development and progression of chronic kidney diseases (CKD).